Abstracts tagged "autoimmune diseases and cancer treatments"

Abstract Number: 1156 • 2017 ACR/ARHP Annual Meeting
Rheumatic Immune Related Adverse Events from Checkpoint Inhibitor Therapy for Cancer: Long-Term Follow up Data
Cassandra Calabrese¹, Elizabeth Kirchner¹, Apostolos Kontzias¹, Laura Wood², Brian Rini², Vamsidhar Velcheti² and Leonard H. Calabrese¹, ¹Rheumatic & Immunologic Disease, Cleveland Clinic Foundation, Cleveland, OH, ²Hematology and Oncology, Cleveland Clinic Foundation, Cleveland, OH
Background/Purpose: The new and emerging field of immune related adverse events (irAEs) from cancer immunotherapies presents many unanswered questions. The spectrum of irAEs is broad…
Abstract Number: 2126 • 2017 ACR/ARHP Annual Meeting
Safety of Immune Checkpoint Inhibitors for the Treatment of Melanoma, Bronchopulmonary and Urologic Neoplasms in Patients with Preexisting Autoimmune Disease
Alice Tison¹, Gilles Quere¹, Laurent Misery¹, Thierry Lesimple², Marie Marcq³, Stephanie Martinez⁴, Florence Brunet-Possenti⁵, Sandrine Mansard⁶, Nathalie Beneton⁷, Mickaël Lambert⁸, Christophe Roge⁸, Ouidad Zehou⁹, Francois Aubin¹⁰, Sarah Maanaoui¹¹, Camille Scalbert¹¹, damien giacchero¹², Nora Kramkimel¹³, François Skowron¹⁴, Anne Pham-Ledard¹⁵, Divi Cornec¹ and Marie Kostine¹⁵, ¹CHU Brest, Brest, France, ²Centre Eugène Marquis, Rennes, France, ³CH Vendee, La Roche-sur-Yon, France, ⁴CH Aix-en-Provence, Aix-en-Provence, France, ⁵CHU Bichat, Paris, France, ⁶CHU Clermont-Ferrand, Clermont-Ferrand, France, ⁷CH Le Mans, Le Mans, France, ⁸CH Morlaix, Morlaix, France, ⁹Hôpital Henri Mondor, Creteil, France, ¹⁰CHU Besancon, Besancon, France, ¹¹CHU Lille, Lille, France, ¹²Centre Antoine Lacassagne, Nice, France, ¹³CHU Cochin, Paris, France, ¹⁴CH Valence, Valence, France, ¹⁵CHU Bordeaux, Bordeaux, France
Background/Purpose: Immune checkpoint inhibitors (ICIs), by inhibiting immunosuppressive molecules overexpressed in the tumoral environment such as CTLA-4 or PD1, increase the anti-tumor immune response and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].